News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Apr 24, 2008

  Insmed to Host First Quarter 2008 Conference Call
• Apr 22, 2008

  Insmed to Present at CBI Follow-On Biologics Conference
• Apr 16, 2008

  Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
• Apr 10, 2008

  Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
• Mar 8, 2008

  Insmed Announces Additional Information in Compliance With NASDAQ Rules
• Mar 4, 2008

  Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
• Feb 28, 2008

  Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
• Feb 19, 2008

  Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
• Feb 11, 2008

  Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
• Feb 5, 2008

  Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
• Feb 5, 2008

  Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
• Jan 28, 2008

  Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
• Jan 22, 2008

  Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market
• Dec 18, 2007

  Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
• Dec 12, 2007

  Insmed Awarded $2.1 Million by Muscular Dystrophy Association
• Dec 6, 2007

  Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
• Dec 6, 2007

  Insmed Appoints Dennis M. Lanfear to Board Of Directors
• Dec 3, 2007

  Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications
• Nov 13, 2007

  Insmed Advances Follow on Biologics Initiative
• Nov 8, 2007

  Insmed Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2007
• Nov 5, 2007

  Insmed Announces Initiation of Phase II Clinical Trial with IPLEX(TM) in Myotonic Muscular Dystrophy
• Oct 24, 2007

  Insmed Announces Third Quarter Earnings Release Date and Conference Call
• Oct 23, 2007

  Insmed to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
• Oct 3, 2007

  Insmed to Present at the 2007 BIO Investor Forum on Wednesday, October 10, 2007
• Aug 2, 2007

  Insmed Reports Financial Results for Second Quarter and First Half of 2007
• Jul 25, 2007

  Insmed Announces Second Quarter and First Half Earnings Release Date and Conference Call
• Jul 9, 2007

  Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
• Jun 26, 2007

  Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
• Jun 25, 2007

  Experienced Biopharmaceutical Executive Steve Glover Joins Insmed; Will Lead Development of Follow-on Biologics
• Jun 19, 2007

  Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
• May 10, 2007

  Insmed Incorporated Reports Financial Results for First Quarter Ended March 31, 2007
• May 7, 2007

  Insmed Announces First Quarter Earnings Release Date and Conference Call
• May 4, 2007

  Insmed Raises Approximately $18.2 Million in Registered Direct Offering
• May 3, 2007

  Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
• May 2, 2007

  Insmed CEO Geoffrey Allan Testifies at Energy and Commerce Committee Hearing
• Apr 30, 2007

  Insmed Releases Positive Results from IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
• Apr 25, 2007

  Insmed Inc. Releases Investor Fact Sheet with Updates on Drug Development Progress
• Mar 26, 2007

  Insmed CEO Geoffrey Allan Testifies at Congressional Hearing
• Mar 16, 2007

  Insmed Announces Additional Information In Compliance With NASDAQ Rules
• Mar 15, 2007

  Insmed Inc. Reports Financial Results for Fourth Quarter and Twelve Months
• Mar 10, 2007

  Update: Insmed to Hold 2006 Q4 and Year End Earnings Results
• Mar 9, 2007

  Insmed to Hold 2006 Q4 and Year End Earnings Results
• Mar 7, 2007

  Insmed Announces Restructure, Settlement Ending IPLEX(TM) Patent Dispute
• Mar 6, 2007

  Insmed to Discuss Litigation Settlement with Tercica
• Jan 10, 2007

  Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
• Dec 13, 2006

  Insmed Announces Positive IPLEX(TM) Product Information At GRS-IGF Society Meeting in Kobe, Japan
• Dec 7, 2006

  Insmed to Host Litigation Update Conference Call
• Dec 6, 2006

  Insmed Patent Litigation Verdict Announced
• Nov 21, 2006

  Insmed to Present at Upcoming Investor Conference in NYC
• Nov 3, 2006

  Insmed Incorporated Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2006

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download